Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
Фаза 3
Идёт, набор закрыт
NCT03043872
| Заболевание | Small Cell Lung Carcinoma Extensive Disease |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | AstraZeneca |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 987 участн. |
|---|
| Вмешательство | Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide |
|---|
| Дата начала | 27.03.2017 |
|---|
| Дата завершения | 27.01.2020 |
|---|
| Публикация результатов | 4.03.2021 |
|---|
Кратко
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer
Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP
From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months). · months
| Global Cohort: D + EP | 13.0 months |
|---|
| Global Cohort: EP | 10.3 months |
|---|
| p-value | 0.0047 |
|---|
| Hazard Ratio (HR) | 0.73 (95% CI 0.591–0.909) |
|---|
OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP
From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months). · months
| Global Cohort: D + T + EP | 10.4 months |
|---|
| Global Cohort: D + EP | 12.9 months |
|---|
| Global Cohort: EP | 10.5 months |
|---|
| p-value | 0.0032 |
|---|
| Hazard Ratio (HR) | 0.75 (95% CI 0.625–0.910) |
|---|
OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP
From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months). · months
| China Cohort: D + EP | 14.4 months |
|---|
| China Cohort: EP | 10.9 months |
|---|
| p-value | 0.0664 |
|---|
| Hazard Ratio (HR) | 0.65 (95% CI 0.414–1.029) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.